NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

People Presenting With Neurocysticercosis in North America

Terminated

Conditions: Neurocysticercosis

First Posted Date: 2014-09-09

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 11

Registration Number: NCT02233855

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 1 locations

Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease

Completed

Conditions: CGD

First Posted Date: 2014-09-08

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 33

Registration Number: NCT02233036

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Phase 2

Completed

Conditions: Myelokathexis
Neutropenia
Warts
Hypogammaglobulinemia
Infections

Interventions: Drug: Plerixafor
Drug: G-CSF

First Posted Date: 2014-09-04

Last Posted Date: 2023-04-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT02231879

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Phase 1

Completed

Conditions: Healthy Adult Immune Responses to Vaccine

Interventions: Biological: VRC-EBOADC069-00-VP
Biological: VRC-EBOADC076-00-VP

First Posted Date: 2014-09-04

Last Posted Date: 2018-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 143

Registration Number: NCT02231866

Locations: 🇺🇸
Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States
🇺🇸
University of Maryland Center for Vaccine Development, Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection

Terminated

Conditions: Latent Tuberculosis Infection

First Posted Date: 2014-08-26

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1

Registration Number: NCT02225158

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Montgomery County Public Health Services, TB, Refugee and Migrant Health, Silver Spring, Maryland, United States

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Phase 2

Completed

Conditions: Avian Influenza

Interventions: Drug: MF59
Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013

First Posted Date: 2014-08-11

Last Posted Date: 2017-07-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 479

Registration Number: NCT02213354

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States

and more 7 locations

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Truvada

First Posted Date: 2014-08-11

Last Posted Date: 2023-07-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 148

Registration Number: NCT02213328

Locations: 🇿🇦
Desmond Tutu HIV Foundation Non-Network CRS, Cape Town, South Africa
🇿🇦
Perinatal HIV Non-network Research CRS, Soweto, South Africa

Impact of Vaccination on Th2 Immunity in Infancy

Terminated

Conditions: Food Hypersensitivity

Interventions: Procedure: Skin prick allergen test
Procedure: Blood draw

First Posted Date: 2014-08-11

Last Posted Date: 2019-07-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 77

Registration Number: NCT02213341

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: AIDSVAX B/E Vaccine
Biological: DNA-HIV-PT123 Vaccine
Biological: Placebo for DNA-HIV-PT123
Biological: Placebo for AIDSVAX B/E

First Posted Date: 2014-08-04

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 104

Registration Number: NCT02207920

Locations: 🇺🇸
Penn Prevention CRS, Philadelphia, Pennsylvania, United States
🇺🇸
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States

and more 4 locations

Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali

Completed

Conditions: Malaria

First Posted Date: 2014-08-01

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 87

Registration Number: NCT02206451

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy